Alpine Immune Sciences (NASDAQ:ALPN) Posts Earnings Results, Beats Expectations By $0.04 EPS
Alpine Immune Sciences (NASDAQ:ALPN) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.64) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.04, Fidelity Earnings reports. The business had revenue of $0.57 million during the quarter, compared to the consensus estimate of $0.25 million.
NASDAQ:ALPN traded up $0.08 during midday trading on Wednesday, reaching $3.58. 1,056 shares of the stock traded hands, compared to its average volume of 12,264. The business has a fifty day moving average of $4.24. Alpine Immune Sciences has a 12 month low of $3.41 and a 12 month high of $8.24. The company has a quick ratio of 7.33, a current ratio of 7.33 and a debt-to-equity ratio of 0.03. The firm has a market capitalization of $68.71 million, a PE ratio of -1.36 and a beta of 1.88.
A number of equities research analysts recently commented on the stock. Zacks Investment Research lowered shares of Alpine Immune Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, July 10th. ValuEngine upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $10.69.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202, a programmed cell death protein ligand 1 (PD-L1)/cytotoxic T-lymphocyte associated protein 4 (CTLA-4) antagonist with PD-L1 dependent CD28 costimulation for the treatment of cancer.
See Also: Correction
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.